Development trend of intelligent manufacturing of plant extracts in China

China is a big exporter of plant extracts, 80% of which are exported in the market However, due to the processing links, quality and quality of extracts, China has no say in international pricing It is found that almost all famous brands of extracts have been occupied by Japan and the United States, while China's plant extracts are still mainly exported in the form of raw materials and primary processed products It has been squeezed in the international market, but now the international trade protectionism is rising, which has more serious market concerns and the possibility of market shock The plant extraction industry feels the chill of economic and trade cooperation Since the first quarter of this year, the export volume of plant extracts has reached more than 300 million US dollars, an increase of 11.5% year-on-year It is the only traditional Chinese medicine commodity that has increased year-on-year, and its growth has driven the export volume of the whole traditional Chinese medicine up The export volume of plant extracts has always been the first in the export of traditional Chinese medicine, and the proportion has gradually increased The export volume has accounted for 47.2% of the total export volume of traditional Chinese medicine (plant extract planting base) at present, the export volume of plant extract in China is mainly some products as food additives In particular, food pigments, with the sharp rise in international market demand, led to the export of the entire plant extract For example, in Mexico and other countries, because the traditional diet is more sensitive to food color, the demand for some food pigments is also large In recent years, the export of Capsicum pigments to Mexico has increased greatly For a long time, the international demand for plant extracts has been relatively stable, with a strong growth momentum It is expected that the export of plant extracts will maintain a steady and rising trend in the second half of the year Moreover, in the adjustment of export tax rebate this year, some plant extract products have recovered from 13% to 15%, which has strengthened the confidence of enterprises in export and will play a greater role in promoting the export of Chinese enterprises Among them, Ginkgo biloba extract, as the main bulk export product of plant extract, has reached US $7 billion in the international market, while the domestic market of hospitals and pharmacies has also far exceeded US $3 billion The huge market of plant extract has become an egg cake competing for by many pharmaceutical companies Although the plant extract market still shows the trend of anti decline under the influence of the financial crisis, the deep-seated problems within the industry have become the shackles for the plant extract to further enter the international market Especially in the production and processing links, the gap with international manufacturers is very obvious In view of this situation, on the basis of intelligent manufacturing 2025 strategy, the state puts forward higher requirements for intelligent manufacturing in the manufacturing and processing links of traditional Chinese medicine and plant extracts In the pharmaceutical industry, due to the characteristics of pharmaceutical production process and management, the production of plant extracts (whether chemical pharmaceutical, biological pharmaceutical or traditional Chinese Medicine) is often a continuous process manufacturing It's just that the process of API production is relatively high, while the discretization of pharmaceutical production is relatively high Therefore, in the pharmaceutical industry, API manufacturing plants or workshops, easy to go information can focus on reference to the form of process manufacturing industry to realize the whole process automation of API production On the basis of the integrated control system, the pharmaceutical production plant or workshop can focus on the intelligent transmission and tracking of materials, first build an intelligent equipment and production line system, and then both gradually realize the construction of "intelligent" factory or digital workshop under the support of the new generation of integrated information platform (plant extract extraction equipment) 1 Automatic perception technology of all kinds of data and information Detection, sensing and analysis technology of various key quality and effective components (such as pat process analysis technology); micro foreign matter detection technology; non-contact detection technology, RFID radio frequency, two-dimensional code, multi-dimensional code label and other tag identification and tracking technology; wireless sensor and communication technology; related video, visual technology, etc 2 New generation of information technology and advanced automation control application technology Internet of things, industrial big data, cloud computing, industrial Internet and other technologies; Internet of things based drug life cycle quality monitoring and Traceability Technology; batch control technology; advanced control technology (APC); fuzzy control technology; MES application technology; IACS integrated control system including ERP, MES, PCs, etc 3 Digital modeling and simulation technology Various modeling, simulation and model-based technologies (MBD based on model definition, mbse based on model system engineering, MBE based on model system enterprise, etc.) 4 Artificial intelligence (AI) Intelligent diagnosis, intelligent optimization, intelligent decision-making and intelligent control technology, etc 5 Application technology of various modules and devices Embedded technology, robot application technology (including AGV transportation), air flow transportation technology, automatic loading and unloading and execution device with special requirements, etc As a special traditional industry, compared with other industries, the most special point of pharmaceutical industry is that it has strict requirements on quality, specification and verification In order to ensure the quality of drugs in all aspects of the whole life cycle from research and development, clinical, production, distribution, operation to use, a set of strict quality management specifications (commonly known as GXP, such as GMP, GCP) has been formulated by domestic and foreign drug regulatory agencies or relevant pharmaceutical organizations based on compliance requirements Therefore, in the future intelligent manufacturing mode of pharmaceutical industry, intelligent process control is a particularly important concern from the compliance requirements (figure below: pharmaceutical process control chart)